Drugs used in Sjögren syndrome with focus on new and upcoming compounds

A tétel rövid nézete
dc.contributor.advisorMegyeri, Attila
dc.contributor.advisordeptDebreceni Egyetem::Gyógyszerésztudományi Karhu_HU
dc.contributor.authorKhosravani, Sarah
dc.contributor.departmentDE--Fogorvostudományi Karhu_HU
dc.contributor.opponentDrimba, László
dc.contributor.opponentSzentmiklósi, József András
dc.contributor.opponentdeptDebreceni Egyetem::Gyógyszerésztudományi Karhu_HU
dc.date.accessioned2018-05-02T05:50:20Z
dc.date.available2018-05-02T05:50:20Z
dc.date.created2018-05-12
dc.description.abstractPrimary Sjögren syndrome, which is amongst the common types of rheumatologic diseases, is classified as a chronic inflammatory process. Sjögren syndrome can present alone (primary SS) or with relation to other systemic autoimmune rheumatic diseases (secondary SS). This autoimmune disease is known for the unique characteristics of dry eyes and dry mouth, specifically affecting the exocrine glands.hu_HU
dc.description.correctorgj
dc.description.correctorhbk
dc.description.coursefogorvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeBSc/BAhu_HU
dc.format.extent41hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/250554
dc.language.isoenhu_HU
dc.subjectSjögren syndromehu_HU
dc.subject.dspaceDEENK Témalista::Orvostudományhu_HU
dc.titleDrugs used in Sjögren syndrome with focus on new and upcoming compoundshu_HU
Fájlok
Gyűjtemények
Theses (Faculty of Dentistry)